Drugs / Mounjaro
Mounjaro cost
tirzepatide · Eli Lilly. Official self-pay prices by strength, what Medicare and savings offers cover, and the cost-related parts of the FDA label.
The short version
- Single-dose pen: lowest listed self-pay price $499 per fill (2.5 mg); highest regular price $499 per fill.[1]
- This listing gives a price for a quantity of 1 and does not say how many days it covers. We are confirming the supply length with Eli Lilly's own pages.[1]
- Medicare GLP-1 Bridge: Mounjaro is not on the program's list of covered drugs.[2]
Mounjaro Single-dose pen: price by strength
Sold through Eli Lilly self-pay (Mounjaro). About this channel.
| Strength | Price per fill | Conditions in the official listing | List price (WAC) |
|---|---|---|---|
| 2.5/0.5 mg | $499 | — | $1,112.16 |
| 5/0.5 mg | $499 | — | $1,112.16 |
| 7.5/0.5 mg | $499 | — | $1,112.16 |
| 10/0.5 mg | $499 | — | $1,112.16 |
| 12.5/0.5 mg | $499 | — | $1,112.16 |
| 15/0.5 mg | $499 | — | $1,112.16 |
“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
Full offer terms: go.lilly.com/terms
Price history
Tracking began Oct 17, 2026. A new row appears only after a person has checked a change against the official page. All changes · Download CSV
| Checked | Form | Strengths | Lowest | Highest regular |
|---|---|---|---|---|
| 2026-10-17 | Single-dose pen | 2.5, 5, 7.5, 10, 12.5, 15 mg | $499 | $499 |
From the FDA label
Word for word from the label on DailyMed: what the drug is approved for, the strengths and pack sizes (how many doses come in one carton or bottle), and the label's dose schedule.
FDA-approved uses · label 1
MOUNJARO® is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Dosage forms and strengths · label 3
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
| Single-dose Pen or Vial |
| 2.5 mg/0.5 mL |
| 5 mg/0.5 mL |
| 7.5 mg/0.5 mL |
| 10 mg/0.5 mL |
| 12.5 mg/0.5 mL |
| 15 mg/0.5 mL |
| Multi-dose Vial (4 doses per vial) | ||
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg/0.6 mL | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg/0.6 mL | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg/0.6 mL | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg/0.6 mL | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg/0.6 mL | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg/0.6 mL | 60 mg/2.4 mL | 25 mg/mL |
| Single-Patient-Use KwikPen (4 doses per KwikPen) | ||
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg | 60 mg/2.4 mL | 25 mg/mL |
Dose schedule in the label · label 2.1
Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].
Recommended Starting Dosage and Escalation
- The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration (2.2)].
- If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
- The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
- 15 mg injected subcutaneously once weekly in adults.
- 10 mg injected subcutaneously once weekly in pediatric patients.
Recommendations Regarding Missed Doses
- If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
- The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
How it is supplied (pack sizes) · label 16
16.1 How Supplied
MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 1 multi-dose vial, or 1 Single-Patient-Use KwikPen as follows:
| Single-Dose Vial and Prefilled Pen | ||
| Strength | 4-pack Single-dose Pen NDC | 1-pack Single-dose Vial NDC |
| 2.5 mg/0.5 mL | 0002-1506-80 | 0002-1152-01 |
| 5 mg/0.5 mL | 0002-1495-80 | 0002-1243-01 |
| 7.5 mg/0.5 mL | 0002-1484-80 | 0002-2214-01 |
| 10 mg/0.5 mL | 0002-1471-80 | 0002-2340-01 |
| 12.5 mg/0.5 mL | 0002-1460-80 | 0002-2423-01 |
| 15 mg/0.5 mL | 0002-1457-80 | 0002-3002-01 |
| Multi-Dose Vial | ||
| Doses per Vial | Strength | 1-pack Multi-dose Vial NDC |
| 4 doses of 2.5 mg/0.6 mL | 10 mg/2.4 mL (4.17 mg/mL) | 0002-4052-11 |
| 4 doses of 5 mg/0.6 mL | 20 mg/2.4 mL (8.33 mg/mL) | 0002-4103-11 |
| 4 doses of 7.5 mg/0.6 mL | 30 mg/2.4 mL (12.5 mg/mL) | 0002-4210-11 |
| 4 doses of 10 mg/0.6 mL | 40 mg/2.4 mL (16.7 mg/mL) | 0002-4304-11 |
| 4 doses of 12.5 mg/0.6 mL | 50 mg/2.4 mL (20.8 mg/mL) | 0002-4523-11 |
| 4 doses of 15 mg/0.6 mL | 60 mg/2.4 mL (25 mg/mL) | 0002-4612-11 |
| Single-Patient-Use KwikPen (with four weekly doses) | ||
| Doses per KwikPen | Strength | 1-pack Single-Patient-Use KwikPen NDC |
| 4 doses of 2.5 mg | 10 mg/2.4 mL (4.17 mg/mL) | 0002-3466-11 |
| 4 doses of 5 mg | 20 mg/2.4 mL (8.33 mg/mL) | 0002-3455-11 |
| 4 doses of 7.5 mg | 30 mg/2.4 mL (12.5 mg/mL) | 0002-3444-11 |
| 4 doses of 10 mg | 40 mg/2.4 mL (16.7 mg/mL) | 0002-3433-11 |
| 4 doses of 12.5 mg | 50 mg/2.4 mL (20.8 mg/mL) | 0002-3422-11 |
| 4 doses of 15 mg | 60 mg/2.4 mL (25 mg/mL) | 0002-3411-11 |
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Official sources for this page
“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
TrumpRx.gov: Mounjaro Single-dose pen listing · as of Oct 17, 2026“Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo® (tablet) Wegovy® (injection or tablet) Zepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens).”
Medicare.gov: Weight loss drugs · as of Oct 17, 2026